LONE TREE, Colo., Sept. 18, 2017 /PRNewswire/ -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics. The company continues to introduce several new products to its product portfolio in its efforts to address the pain and rehabilitation markets and the current opioid epidemic.
Given American's current crisis with opioid addiction, Zynex is committed to providing health care professionals a variety of prescription-strength options without side-effects. This has never been more necessary than it is today considering the staggering statistics.
- Pain impacts the lives of more Americans than diabetes, heart disease and cancer combined.
- Pain is the leading cause of disability and the most common reason American's seek health care is because they are seeking treatment for acute or chronic pain.
- 1 in every 4 Americans (76.2 million people), suffer with pain that lasts longer than 24 hours.
- Approximately 25.3 million adults struggle with chronic pain, pain every day that has been present for more than 3 months.
- If pharmaceuticals such as opioids continue to be used as the first line of defense America will continue to see a rise in opioid misuse, addiction and drug-related deaths.
Aware of the current issues, Zynex has a dedicated team working to expand the product line beyond electrotherapy alone. Zynex has added new products such as JetStream Hot/Cold Therapy, Aspen LSO Backbracing and Comfortrac cervical traction, all products targeted at treating acute as well as chronic pain without side-effects.
Zynex is committed to making prescription strength drug-free options more accessible to patients and easier for physicians to prescribe as a first line defense rather than prescribing opioid pharmaceuticals.
Thomas Sandgaard, Founder and CEO commented: "Our prescription-strength NexWave device is already available nationwide and I am excited that we are now able to offer traction, low back support and cold/hot therapy as an effective alternative for physicians to prescribe for patients with severe pain.
I strongly believe that any effort to provide opioid free treatment can improve the lives of millions of Americans living with pain, slow down the too frequent path to addiction and hopefully save many lives. We are currently experiencing a horrific epidemic in this country and I am committed to be part of a healthy solution to the problem.
As we continue to expand our sales force and increase our presence across the country, all of these products will become more accessible. In an effort to provide more details about Zynex prescription-strength products, we are developing a National Webcast service designed to educate health care providers on our product line and the ease of prescribing. Our EZ-Rx program makes it easy for physicians everywhere in the U.S. to offer drug-free solutions to their efforts of pain management."
About Zynex
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers, a non-invasive device to monitor fluid imbalance. For additional information, please visit: Zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our international expansion efforts, our ability to engage additional sales representatives and their success, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation, our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website.
Contact: Zynex, Inc. (303) 703-4906
Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content with multimedia:http://www.prnewswire.com/news-releases/zynex-continues-fight-against-opioid-abuse-and-expands-its-arsenal-of-pain-relief-products-300521188.html
SOURCE Zynex
